Want to see HK:2576 full AI Analyst Report?
Top Page
Zhejiang Taimei Medical Technology Co Ltd Class H
(2576)
Select Model
Select Model
Rating:51Neutral
Price Target:
HK$5.50
▲(30.95% Upside)
Action:Reiterated
Date:07/08/26
The score is primarily constrained by continued losses and negative free cash flow despite operational improvement, which keeps financial risk elevated. Technically, the uptrend is strong, but momentum is overextended (high RSI/Stoch). Valuation remains challenged due to negative earnings and no dividend yield provided.
Positive Factors
Revenue rebound
The sharp 2025 revenue rebound indicates substantially stronger commercial activity and renewed demand compared with prior years. If the improvement persists, a larger revenue base can support operating leverage, broaden market reach, and provide a foundation for a more durable recovery.
Negative Factors
Unproven profitability
Despite revenue and margin improvement, negative EBIT and EBITDA show that the core operation has not yet converted growth into sustainable operating earnings. Until this changes, the turnaround remains unproven and future performance depends on continued execution and cost discipline.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
The sharp 2025 revenue rebound indicates substantially stronger commercial activity and renewed demand compared with prior years. If the improvement persists, a larger revenue base can support operating leverage, broaden market reach, and provide a foundation for a more durable recovery.
Read all positive factors
Zhejiang Taimei Medical Technology Co Ltd Class H (2576) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.92B
Dividend YieldN/A
Average Volume (3M)943.05K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees681
SectorGeneral
Sector StrengthN/A
IndustrySoftware - Application
Share Statistics
EPS (TTM)-0.12
Shares Outstanding200,592,530
10 Day Avg. Volume889,220
30 Day Avg. Volume943,053
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)1.79
Price to Sales (P/S)4.02
P/FCF Ratio-46.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zhejiang Taimei Medical Technology Co Ltd Class H Business Overview & Revenue Model
Company Description
Zhejiang Taimei Medical Technology Co., Ltd., established in 2013 and based in Jiaxing, China, specializes in delivering sophisticated digital operational platforms specifically designed for the biopharmaceutical industry across the country. The c...
Zhejiang Taimei Medical Technology Co Ltd Class H Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
72
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 531.96M | 499.28M | 551.16M | 573.14M | 549.22M | 466.18M |
| Gross Profit | 235.10M | 211.91M | 224.94M | 179.00M | 185.40M | 163.59M |
| EBITDA | -74.54M | -29.11M | -176.73M | -302.97M | -364.38M | -440.39M |
| Net Income | -65.15M | -41.74M | -214.61M | -346.78M | -412.91M | -479.61M |
Balance Sheet | ||||||
| Total Assets | 1.50B | 1.56B | 1.58B | 1.44B | 1.83B | 1.80B |
| Cash, Cash Equivalents and Short-Term Investments | 1.08B | 1.19B | 1.20B | 1.07B | 1.41B | 1.40B |
| Total Debt | 85.39M | 61.16M | 34.76M | 28.64M | 81.47M | 77.44M |
| Total Liabilities | 348.40M | 365.62M | 348.62M | 402.56M | 441.97M | 393.75M |
| Stockholders Equity | 1.08B | 1.12B | 1.16B | 978.33M | 1.31B | 1.41B |
Cash Flow | ||||||
| Free Cash Flow | 6.67M | -43.15M | -207.30M | -360.64M | -357.44M | -249.94M |
| Operating Cash Flow | 8.54M | -39.38M | -201.62M | -351.16M | -329.22M | -217.53M |
| Investing Cash Flow | 328.77M | 328.99M | -283.68M | 237.69M | -5.88M | -379.35M |
| Financing Cash Flow | 41.46M | 24.90M | 281.04M | -39.28M | 285.59M | -40.08M |
Zhejiang Taimei Medical Technology Co Ltd Class H Technical Analysis
Negative
4.20
Price Trends
5.73
Negative
5.27
Negative
4.84
Positive
Market Momentum
-0.13
Positive
39.10
Neutral
44.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2576, the sentiment is Negative. The current price of 4.2 is below the 20-day moving average (MA) of 5.44, below the 50-day MA of 5.73, and below the 200-day MA of 4.84, indicating a neutral trend. The MACD of -0.13 indicates Positive momentum. The RSI at 39.10 is Neutral, neither overbought nor oversold. The STOCH value of 44.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2576.
Zhejiang Taimei Medical Technology Co Ltd Class H Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$1.10B | 7.55 | 21.83% | 6.41% | 35.78% | 131.58% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | HK$1.08B | 51.95 | 21.60% | ― | 151.97% | ― | |
51 Neutral | HK$2.92B | -37.01 | -5.91% | ― | ― | ― | |
44 Neutral | HK$105.83M | 25.14 | -8.43% | ― | 67.24% | ― |
* General Sector Average
HK:2576
Zhejiang Taimei Medical Technology Co Ltd Class H
5.00
0.35
7.53%
HK:1450
Century Sage Scientific Holdings Ltd
0.78
-0.14
-14.94%
HK:8148
Aurum Pacific (China) Group Ltd.
2.49
1.65
199.40%
HK:8156
Sinopharm Tech Holdings Limited
0.19
-0.07
-28.46%
Zhejiang Taimei Medical Technology Co Ltd Class H Corporate Events
Zhejiang Taimei Posts Higher Revenue but Wider Interim Loss
Aug 26, 2026
Zhejiang Taimei Medical Technology reported revenue of RMB263.6 million for the six months ended June 30, 2026, an 8% increase year-on-year, with gross profit rising 17.5% and margin improving to 44.7%. Despite higher sales and other income, the G...
Zhejiang Taimei Schedules Board Meeting to Approve Interim Results and Mull Dividend
Aug 14, 2026
Zhejiang Taimei Medical Technology Co., Ltd. has scheduled a board meeting for August 26, 2026 to review and approve the group’s interim results for the six months ended June 30, 2026 and to authorize their publication. The board will also c...
Zhejiang Taimei Medical Approves Board, Governance Changes at 2025 AGM
Jun 23, 2026
Zhejiang Taimei Medical Technology Co., Ltd. held its 2025 annual general meeting in Shanghai, convened by the board and chaired by executive director and board chairman Dr. Zhao Lu. The meeting was conducted in accordance with PRC company law and...
Zhejiang Taimei Wins Mandate for Up to 10% H-Share Buyback
Jun 23, 2026
Zhejiang Taimei Medical Technology has received shareholder approval for a general mandate allowing its board to repurchase up to 10% of the company’s issued H shares, excluding treasury stock, on the Hong Kong market. The buyback, funded fr...
Zhejiang Taimei Re-elects Dong Xiaohan as Employee Representative Supervisor
Jun 23, 2026
Zhejiang Taimei Medical Technology Co., Ltd. has re-elected Ms. Dong Xiaohan as the company’s employee representative supervisor, following a vote at an employee representatives’ meeting on June 23, 2026. She will serve on the third se...
Zhejiang Taimei Medical Technology Updates Board and Committee Structure
Jun 23, 2026
Zhejiang Taimei Medical Technology has released an updated list of its board of directors, detailing the roles of executive and independent non-executive directors, including the chairman and general manager. The announcement underscores the compa...
Zhejiang Taimei Shareholders Approve All Resolutions at 2026 Extraordinary Meeting
Jun 8, 2026
Zhejiang Taimei Medical Technology Co., Ltd. reported that all resolutions proposed at its second extraordinary general meeting of 2026 were approved by shareholders via poll, underscoring broad investor support. The meeting, held in Shanghai and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.